Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib plus acitretin vs acitretin alone for primary cutaneous amyloidosis (retrospective cohort)
ChiCTR2600124084Phase 4Completed
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- May 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tofacitinib and acitretin in primary cutaneous amyloidosis (PCA), Macular Amyloidosis and lichen amyloidosis (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Composite clinical response rate at week 12. Started May 2026; status: completed.
02
Drugs
tofacitinibacitretin
03
Conditions
primary cutaneous amyloidosis (PCA)Macular Amyloidosislichen amyloidosis
Beyond the preview
Go deeper on ChiCTR2600124084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124084.